Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research
File(s)
Published version
Author(s)
Malisa, Jemima
Manak, Mark
Michelo, Clive
Imami, Nesrina
Kibirige, Catherine N
Type
Journal Article
Abstract
There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring. It is estimated that only 75% of people living with HIV (PLWH) worldwide have access to viral load testing. In LMICs, this figure is below 50%. In a recent WHO survey in mostly LMICs, 21 out of 30 countries surveyed found HIV-1 first-line pre-treatment drug resistance in over 10% of study participants. In the worst-affected regions, up to 68% of infants born to HIV-1 positive mothers were found to harbour first-line HIV-1 treatment resistance. This is a huge public health concern. Greater access to treatment-monitoring is required in LMICs if the UNAIDS "third 95" targets are to be achieved by 2030. Here, we review the current challenges of viral load testing and present the case for greater utilization of Laboratory-based assays that quantify intracellular HIV-1 RNA and/or DNA to provide broader worldwide access to HIV-1 surveillance, drug-resistance monitoring, and cure-research.
Date Issued
2023-03-20
Date Acceptance
2023-03-06
Citation
Scientific Reports, 2023, 13, pp.1-7
ISSN
2045-2322
Publisher
Nature Portfolio
Start Page
1
End Page
7
Journal / Book Title
Scientific Reports
Volume
13
Copyright Statement
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/36941272
PII: 10.1038/s41598-023-31103-y
Subjects
Anti-HIV Agents
HIV Infections
HIV Seropositivity
HIV-1
Humans
Infant
Viral Load
Publication Status
Published
Coverage Spatial
England
Article Number
4578
Date Publish Online
2023-03-20